Tempest Reports Year End 2022 Financial Results and Provides Business Update

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first half of 2023 New data on TPST-1120 biomarker and proprietary small molecule TREX1 inhibitor accepted for presentation at AACR 2023 TPST-1495 Phase 1 monotherapy and combination dose escalation and optimization ongoing, with initial data release planned by mid 2023 BRISBANE, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year...

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

– SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS – – Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at American Association for Cancer Research (AACR) Annual Meeting in April 2023 – – Cash, cash equivalents, and short-term investments of $98.6 million as of December 31, 2022; continue to expect cash runway through at least 1Q 2024 – SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter...

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, March 22, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced financial results for the year ended December 31, 2022. Additionally, the Company announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. The resulting changes include discontinuing the development of onapristone extended release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate. “Given the challenging...

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022 Cash and cash equivalents of €38.8 million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer,...

ECN Capital Reports US$0.02 in Adjusted Net Income per Common Share in Q4-2022

Written by Customer Service on March 22, 2023. Posted in Dividend Reports And Estimates.

Review of Strategic Alternatives Initiated to Maximize Long-Term Growth and Value TORONTO, March 22, 2023 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or the “Company”) today reported financial results for the three-month period and year ended December 31, 2022. For the three-month period ended December 31, 2022, ECN Capital reported Adjusted net income applicable to common shareholders from continuing operations of $4.1 million or $0.02 per share (basic) versus $11.8 million or $0.05 per share (basic) for the previous three-month period and net loss of $.5 million or $0.00 per share (basic) for the same period last year. For the twelve-month period, the Company reported Adjusted net Income applicable to common shareholders of $30.7 million or $0.12 per share (basic) versus $0.9 million or $0.00 per share (basic)...

CVB Financial Corp. Announces 134th Consecutive Cash Dividend

Written by Customer Service on March 22, 2023. Posted in Dividend Reports And Estimates.

ONTARIO, Calif., March 22, 2023 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the first quarter of 2023. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on March 22, 2023. The quarterly dividend will be payable on or about April 19, 2023 to shareholders of record as of April 5, 2023. “We are pleased to announce our 134th consecutive cash dividend paid to our shareholders. This speaks to the continuing stability of Citizens Business Bank’s customer focused business model during uncertain times,” said David A. Brager, President and Chief Executive Officer. Corporate Overview CVB Financial Corp. (“CVBF”) is the holding company for Citizens Business Bank. CVBF is one of the 10 largest bank...

Wilhelmina International, Inc. Announces Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

Annual Financial Highlights Annual revenues of $17.8 million for 2022 improved by 10.4% from the prior year. Annual operating income of $2.4 million for 2022 was the highest since 2014. Annual net cash flows provided by operating activities were $2.5 million in 2022. Annual pre-tax income of $2.6 million, net income of $3.5 million and Pre-Corporate EBITDA of $3.9 million for 2022. $12.0 million cash and cash equivalents at December 31, 2022 was the highest balance at the end of any quarterly or annual period in Company history Annual gross billings of $70.0 million for 2022 improved 17.9% from the prior year. (in thousands) Q4 22 Q4 21 YOYChange Year Ended 2022 Year Ended 2021 YOYChange Total Revenues $ 4,091 $ 4,294 (4.7%) $ 17,780 $ 16,102 10.4% Operating (Loss) Income (166 ) 149 (211.4%) 2,419 2,158 12.1% (Loss)...

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Written by Customer Service on March 22, 2023. Posted in Earnings Releases And Operating Results.

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program. The Company previously reported clinical data in adult patients with MELAS* that indicate that zagociguat may have potential as a first-ever therapy for patients with this rare, genetic mitochondrial disease. In Q4 2022, Cyclerion met with the United States Food and Drug Administration (FDA) and incorporated feedback from regulatory and mitochondrial disease clinical experts to refine the design of a Phase 2b study to evaluate zagociguat in patients with MELAS. More recently, Cyclerion filed a request with the FDA for Orphan Drug Designation and manufactured drug product to support the Phase 2b study. Given the significant...

Supply & Demand Chain Executive Recognizes Wabash’s Richard Mansilla with 2023 Pros to Know Award

Written by Customer Service on March 22, 2023. Posted in Public Companies.

LAFAYETTE, Ind., March 22, 2023 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC), the visionary leader of connected solutions for the transportation, logistics and distribution industries, congratulates Vice President, Global Procurement Richard Mansilla who is recognized by Supply & Demand Chain Executive as one of the winners of the 2023 Pros to Know award. Supply & Demand Chain Executive is the only publication covering the entire global supply chain. The annual Pros to Know award recognizes outstanding executives whose accomplishments offer a roadmap for other leaders looking to leverage supply chain for competitive advantage. Winners are selected based on their professional achievements, innovations and solutions. “This year’s list is filled with supply chain professionals whose achievements and success stories have helped...

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Written by Customer Service on March 22, 2023. Posted in Public Companies.

SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there...

Day: March 22, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice